{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:10:06Z","timestamp":1794633006901,"version":"4.9.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Now effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize its risk\/benefit ratio is crucial. The American Joint Committee on Cancer staging system is the most widely used and validated melanoma staging system, which recently released its 8th edition. We aimed to externally validate the prognostic and discriminatory ability for survival of the 8th edition compared to the 7th edition and evaluate prognostic factors. Prospective database of stage III melanoma (2000\u20132016). Prognostic factors for melanoma-specific survival and distant metastasis-free survival were analyzed. Survival differentiation of the 7th and 8th edition was assessed with log-rank tests and Cox proportional hazards models. Discriminatory ability was compared using the receiver operating characteristic and Akaike's Information Criterion. Six hundred forty patients were included (median follow-up 59 months). Median melanoma-specific survival was 138 months, distant metastasis-free survival 96 months. Age, Breslow thickness, ulceration of the primary tumor and number of positive lymph nodes (N) were independent prognostic parameters for distant metastasis-free survival and melanoma-specific survival. The 8th edition performed slightly better than the 7th edition in terms of survival discrimination but showed slightly worse distant metastasis-free survival and melanoma-specific survival differentiation between stage IIIA and IIIB. Sentinel node (SN) metastasis size cutoff of 1 mm differentiated survival in both 7th and 8th edition stage IIIA, showing excellent distant metastasis-free survival and melanoma-specific survival for patients with a SN metastasis size &lt;1 mm. The 8th edition performed at least comparably, if not better than the 7th in terms of survival discrimination. However, survival in both 7th and 8th edition stage IIIA melanoma remains heterogeneous. EORTC SN tumor burden criteria can further stratify survival and help patient selection for adjuvant therapy.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000643","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T05:10:07Z","timestamp":1571980207000},"page":"185-192","source":"Crossref","is-referenced-by-count":22,"title":["External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?"],"prefix":"10.1097","volume":"30","author":[{"given":"Max F.","family":"Madu","sequence":"first","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Franke","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A.","family":"Van de Wiel","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M.C.","family":"Klop","sequence":"additional","affiliation":[{"name":"Head and Neck Surgery and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W.J.M.","family":"Wouters","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma.","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1445-5994.2001.01282.x","article-title":"Sentinel lymph node biopsy in patients with melanoma and breast cancer.","volume":"31","author":"Uren","year":"2001","journal-title":"Intern Med J"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2017.09.002","article-title":"Immediate completion lymph node dissection (CLND) in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumor burden criteria.","volume":"87","author":"Madu","year":"2017","journal-title":"Eur J Cancer"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.ejca.2009.08.015","article-title":"Expert opinion in melanoma: the sentinel node; EORTC melanoma group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden.","volume":"45","author":"van Akkooi","year":"2009","journal-title":"Eur J Cancer"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma.","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.2016.71.9393","article-title":"Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis.","volume":"35","author":"Haydu","year":"2017","journal-title":"J Clin Oncol"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","article-title":"The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients.","volume":"50","author":"van der Ploeg","year":"2014","journal-title":"Eur J Cancer"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","article-title":"Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and dewar topography criteria.","volume":"29","author":"van der Ploeg","year":"2011","journal-title":"J Clin Oncol"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","article-title":"Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.","volume":"28","author":"Balch","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/bcr2464","article-title":"PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.","volume":"12","author":"Wishart","year":"2010","journal-title":"Breast Cancer Res"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","article-title":"Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.","volume":"19","author":"Ravdin","year":"2001","journal-title":"J Clin Oncol"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer.","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer.","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:07:30Z","timestamp":1693627650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000643","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}